tirzepatide lab analysis reduces food intake and appetite, and affects brain functioning, more than placebo and liraglutide Tirzepatide (GLP-1/GIP) – Weight Loss

This peptide is increasingly used as an anti-obesity medication and complements any fat loss program , including low-carb, ketogenic, or intermittent fasting diets

Results found GHK-Cu to be associated with less brain damage, reduced neuronal loss and improved function

This rapid clearance might suggest the need for larger doses, yet the peptide initiates cellular processes that continue long after the compound itself has been metabolized

Expected weight loss by starting weight Based on SURMOUNT-1 data showing 15 to 21% body weight reduction over 72 weeks: Starting at 200 pounds: Expected loss of 30 to 42 pounds over 72 weeks (ending at 158 to 170 pounds)